The Hyperparathyroidism drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperparathyroidism. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperparathyroidism and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Hyperparathyroidism by 16 companies/universities/institutes. The top development phase for Hyperparathyroidism is preclinical with four drugs in that stage. The Hyperparathyroidism pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hyperparathyroidism pipeline products market are: Amgen, Vifor-Fresenius Medical Care Renal Pharma and Vidasym.
The key targets in the Hyperparathyroidism pipeline products market include Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Calcium Sensing Receptor, and Vitamin D Receptor.
The key mechanisms of action in the Hyperparathyroidism pipeline product include Calcium Sensing Receptor Agonist with three drugs in Pre-Registration. The Hyperparathyroidism pipeline products include four routes of administration with the top ROA being Oral and four key molecule types in the Hyperparathyroidism pipeline products market including Small Molecule, and Monoclonal Antibody.
Hyperparathyroidism overview
Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. In hyperparathyroidism, one or more of parathyroid glands becomes overactive and makes excess PTH. This could be due to a tumor, gland enlargement, or other structural problems of the parathyroid glands.Symptoms of hyperparathyroidism are caused by inappropriately normal or elevated blood calcium leaving the bones and flowing into the blood stream in response to increased production of parathyroid hormone. Hyperparathyroidism can cause hyperchloremia and increase renal bicarbonate loss, which may result in a normal anion gap metabolic acidosis. The gold standard of diagnosis is the PTH immunoassay.
For a complete picture of Hyperparathyroidism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
